|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||323.00 - 333.50|
|52 Week Range||299.01 - 430.00|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||18.42|
|Forward Dividend & Yield||9.97 (2.96%)|
|Ex-Dividend Date||Mar 17, 2022|
|1y Target Est||N/A|
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
SOUTH SAN FRANCISCO, Calif., August 02, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-smal